{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:56Z","timestamp":1787009456289,"version":"build-2736575974"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With the adoption of safer outpatient cancer care practices, much of cancer care has transitioned to outpatient settings, decreasing the need for inpatient systemic therapy (IST), which is associated with poorer end-of-life outcomes. We evaluated reasons for IST use, palliative care (PC) utilization, and outcomes among IST recipients to inform guidelines on appropriate IST use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We conducted a retrospective chart review of all IST admissions at an academic center from January 2016 to December 2017. Patients were stratified by solid tumor (ST) vs hematological malignancies (HM). We recorded IST urgency, response, mortality, and other variables. Descriptive statistics and odds ratios were estimated from logistic regression models with mixed effects to account for multiple admissions per patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We analyzed 893 admissions (19% ST) among 620 patients. HM patients required frequent elective IST admissions than ST (P &amp;lt; .0001). ST patients more often received IST for non-urgent indications (P\u2009=\u2009.0032) during non-cancer-related admissions. ST patients had fewer responses to IST compared to HM (36% vs 70%; P\u2009&amp;lt;\u2009.0001). PC services were more likely utilized for ST vs HM patients (48% vs 14%; P &amp;lt; .0001) and were associated with increased rates of health care proxy assignment, code status change, and hospice discharge. Early 60-day mortality was higher for ST vs HM patients (17.3% vs 5.8%; P\u2009&amp;lt;\u2009.001), and most patients (55%) died inpatient during the index admission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IST was overutilized in ST patients with poor response rates and significant early mortality. PC service utilization rates remain low but improved end-of-life transition planning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf214","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:54:24Z","timestamp":1761656064000},"source":"Crossref","is-referenced-by-count":2,"title":["Examining inpatient chemotherapy utilization among patients with cancer and impact on outcomes"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3166-4355","authenticated-orcid":false,"given":"Giulia","family":"Petrone","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine , St. Louis, MO 63110,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Handa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, The Ohio State University Wexner Medical Center , Columbus, OH 43210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Anderson","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute , New York, NY 10029,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobel","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Zucker School of Medicine, Northwell Health , Hempstead, NY 11549,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deukwoo","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Population Health Science and Policy, Icahn School of Medicine , New York, NY 10029,","place":["United States"]},{"name":"Division of Clinical and Translational Sciences, Department of Internal Medicine, University of Texas Health Science Center at Houston , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Jain","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute , New York, NY 10029,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti S","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute , New York, NY 10029,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cardinale B","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9161-0817","authenticated-orcid":false,"given":"Natalie S","family":"Berger","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Columbia University Irving Medical Center\/New York Presbyterian-Hudson Valley Hospital , Cortlandt Manor, NY 10567,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"2025112211171123600_oyaf214-B1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jamaoncol.2015.2378","article-title":"Chemotherapy use, performance status, and quality of life at the end of life","volume":"1","author":"Prigerson","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025112211171123600_oyaf214-B2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12904-019-0427-4","article-title":"Inpatient palliative chemotherapy is associated with high mortality and aggressive end-of-life care in patients with advanced solid tumors and poor performance status","volume":"18","author":"de Vasconcellos","year":"2019","journal-title":"BMC Palliat Care"},{"key":"2025112211171123600_oyaf214-B3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1200\/JCO.2022.40.28_suppl.300","article-title":"The inpatient immunotherapy outcomes study: a multicenter retrospective study of patients treated with immune checkpoint inhibitors in the inpatient setting","volume":"40","author":"Riaz","year":"2022","journal-title":"JCO"},{"key":"2025112211171123600_oyaf214-B4","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1177\/10781552221123967","article-title":"Inpatient utilization of immune checkpoint inhibitors and clinical outcomes","volume":"29","author":"Wang","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"2025112211171123600_oyaf214-B5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/onco.13561","article-title":"Clinical outcomes of patients with metastatic cancer receiving immune checkpoint inhibitors in the inpatient setting","volume":"26","author":"Durbin","year":"2021","journal-title":"Oncologist"},{"key":"2025112211171123600_oyaf214-B6","first-page":"52","article-title":"The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4","volume":"14","author":"Teixeira","year":"2015","journal-title":"Clin Color Cancer"},{"key":"2025112211171123600_oyaf214-B7","doi-asserted-by":"crossref","first-page":"e19527","DOI":"10.1200\/jco.2012.30.15_suppl.e19527","article-title":"Palliative inpatient chemotherapy: clinical benefit or harm?","volume":"30","author":"Ali","year":"2012","journal-title":"JCO"},{"key":"2025112211171123600_oyaf214-B8","doi-asserted-by":"crossref","first-page":"e014661","DOI":"10.1136\/bmjopen-2016-014661","article-title":"Treatment targeted at underlying disease versus palliative care in terminally ill patients: a systematic review","volume":"7","author":"Reljic","year":"2017","journal-title":"BMJ Open."},{"key":"2025112211171123600_oyaf214-B9","first-page":"2755","article-title":"Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile","volume":"30","author":"Banh","year":"2022","journal-title":"Support Care Cancer."},{"key":"2025112211171123600_oyaf214-B10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1200\/JOP.2015.010462","article-title":"The state of cancer care in America, 2016: a report by the American Society of Clinical Oncology","volume":"12","year":"2016","journal-title":"J Oncol Pr"},{"key":"2025112211171123600_oyaf214-B11","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/jnci\/djab192","article-title":"Annual report to the nation on the status of cancer, part 2: patient economic burden associated with cancer care","volume":"113","author":"Yabroff","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2025112211171123600_oyaf214-B12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/10463356.2021.1927629","article-title":"Transitioning select chemotherapeutics to the outpatient setting improves care and reduces costs","volume":"36","author":"Mcbride","year":"2021","journal-title":"Oncol Issues"},{"key":"2025112211171123600_oyaf214-B13","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025112211171123600_oyaf214-B14","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/EDBK_201441","article-title":"Tumor response assessment for precision cancer therapy: response evaluation criteria in solid tumors and beyond","volume":"38","author":"Nishino","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"2025112211171123600_oyaf214-B15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1634\/theoncologist.1-1-107","article-title":"Guidelines for hospitalization for chemotherapy","volume":"1","author":"Dollinger","year":"1996","journal-title":"Oncologist"},{"key":"2025112211171123600_oyaf214-B16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ajh.22268","article-title":"Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia","volume":"87","author":"Saini","year":"2012","journal-title":"Am J Hematol"},{"key":"2025112211171123600_oyaf214-B17","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.2146\/ajhp180060","article-title":"Transitioning historically inpatient chemotherapy regimens for hematologic malignancies to the ambulatory care setting","volume":"75","author":"Moore","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"2025112211171123600_oyaf214-B18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/bloodadvances.2019000707","article-title":"Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"4","author":"Mabrey","year":"2020","journal-title":"Blood Adv"},{"key":"2025112211171123600_oyaf214-B19","doi-asserted-by":"crossref","first-page":"e644","DOI":"10.1200\/JOP.18.00738","article-title":"Reducing hospitalizations: institution of outpatient infusional EPOCH-based chemotherapy at a safety net hospital","volume":"15","author":"Keshvani","year":"2019","journal-title":"J Oncol Pract"},{"key":"2025112211171123600_oyaf214-B20","doi-asserted-by":"crossref","first-page":"e172450-e172450","DOI":"10.1001\/jamaoncol.2017.2450","article-title":"Trends in adult cancer\u2013related emergency department utilization: an analysis of data from the nationwide emergency department sample","volume":"3","author":"Rivera","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025112211171123600_oyaf214-B21","doi-asserted-by":"crossref","first-page":"e190979","DOI":"10.1001\/jamanetworkopen.2019.0979","article-title":"Analysis of diagnoses, symptoms, medications, and admissions among patients with cancer presenting to emergency departments","volume":"2","author":"Caterino","year":"2019","journal-title":"JAMA Netw Open."},{"key":"2025112211171123600_oyaf214-B22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12904-019-0428-3","article-title":"Impact of palliative chemotherapy and best supportive care on overall survival and length of hospitalization in patients with incurable cancer: a 4-year single institution experience in Japan","volume":"18","author":"Murakawa","year":"2019","journal-title":"BMC Palliat Care."},{"key":"2025112211171123600_oyaf214-B23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/COC.0000000000000880","article-title":"Factors affecting inpatient mortality and length of stay in nonmetastatic colorectal cancer","volume":"45","author":"Ulanja","year":"2022","journal-title":"Am J Clin Oncol"},{"key":"2025112211171123600_oyaf214-B24","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1634\/theoncologist.2008-0257","article-title":"Factors that affect the duration of the interval between the completion of palliative chemotherapy and death","volume":"14","author":"Hashimoto","year":"2009","journal-title":"Oncologist"},{"key":"2025112211171123600_oyaf214-B25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/bmjspcare-2019-001770","article-title":"Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care","volume":"9","author":"Bylicki","year":"2019","journal-title":"BMJ Support Palliat Care."},{"key":"2025112211171123600_oyaf214-B26","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non\u2013small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"key":"2025112211171123600_oyaf214-B27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/jso.25499","article-title":"Timing of palliative care: when to call for a palliative care consult","volume":"120","author":"Schlick","year":"2019","journal-title":"J Surg Oncol"},{"key":"2025112211171123600_oyaf214-B28","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2009.0031","article-title":"Palliative care","volume":"7","author":"Levy","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"2025112211171123600_oyaf214-B29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.2016.70.1474","article-title":"Integration of palliative care into standard oncology care: American Society of Clinical Oncology Clinical Practice Guideline update","volume":"35","author":"Ferrell","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025112211171123600_oyaf214-B30","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.21037\/apm-19-504","article-title":"Barriers to inpatient palliative care consultation among patients with newly diagnosed cancer after emergency admission","volume":"9","author":"Higashibata","year":"2020","journal-title":"Ann Palliat Med"},{"key":"2025112211171123600_oyaf214-B31","first-page":"e13172","article-title":"The COMPASS study: a descriptive study on the characteristics of palliative care team consultation for cancer patients in hospitals","volume":"29","author":"Brinkman-Stoppelenburg","year":"2020","journal-title":"Eur J Cancer Care"},{"key":"2025112211171123600_oyaf214-B32","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(13)62416-2","article-title":"Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial","volume":"383","author":"Zimmermann","year":"2014","journal-title":"Lancet."},{"key":"2025112211171123600_oyaf214-B33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2022.40.28_suppl.020","article-title":"Novel use of an objective scoring rubric to guide inpatient chemotherapy stewardship","volume":"40","author":"Bhardwaj","year":"2022","journal-title":"JCO"},{"key":"2025112211171123600_oyaf214-B34","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3332\/ecancer.2018.831","article-title":"Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1","volume":"12","author":"Caires-Lima","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"2025112211171123600_oyaf214-B35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s44228-022-00003-9","article-title":"Trends in inpatient chemotherapy hospitalizations, cost and mortality for patients with acute leukemias and myeloma","volume":"4","author":"Gil","year":"2022","journal-title":"Clin Hematol Int"},{"key":"2025112211171123600_oyaf214-B36","article-title":"Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline","volume":"6","author":"Chiorean","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"2025112211171123600_oyaf214-B37","doi-asserted-by":"crossref","first-page":"e202488","DOI":"10.1001\/jamanetworkopen.2020.2488","article-title":"Comparison of drugs used for adjuvant and metastatic therapy of colon, breast, and non\u2013small cell lung cancers","volume":"3","author":"Parsons","year":"2020","journal-title":"JAMA Netw Open."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf214\/65041846\/oyaf214.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf214\/65041846\/oyaf214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf214\/65041846\/oyaf214.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:17:21Z","timestamp":1763828241000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf214\/8306834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf214","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,30]]},"article-number":"oyaf214"}}